Pharmacological hypothermia: a potential for future stroke therapy?

Area of Science:

• Neuroscience
• Pharmacology
• Therapeutics

Background:

• Mild physical hypothermia improves stroke outcomes.
• Clinical translation of hypothermia is limited by temperature control, patient intolerance, and immunosuppression.
• Pharmacological induction of hypothermia is being investigated in animal models for stroke treatment.

Purpose of the Study:

• To review eight classes of pharmacological agents with hypothermic effects.
• To summarize proposed mechanisms of action and side effects of these agents.
• To present reported thermoregulatory effects and discuss potential combination therapies.

Main Methods:

• Literature review of pharmacological agents inducing hypothermia.
• Categorization of agents into eight classes: cannabinoid, opioid, TRPV1, neurotensin, thyroxine derivatives, dopamine, gas, and adenosine.
• Summary of proposed mechanisms, side effects, and thermoregulatory effects.

Main Results:

• Eight classes of drugs exhibit hypothermic effects via diverse mechanisms.
• Drugs in TRPV1, neurotensin, and thyroxine families can modulate thermoregulatory responses.
• Potential for combination therapy with physical hypothermia to enhance temperature control.

Conclusions:

• Pharmacological agents offer a potential avenue to overcome limitations of physical hypothermia.
• Combination therapies may provide faster and more stable temperature regulation post-stroke.
• Further research into these drug classes could advance hypothermia treatment for stroke.